论文部分内容阅读
氨苯异喹(Nomifensine)是一种“第二代抗抑郁剂”,去年在美国开始推荐应用,据称它与三环类抗抑郁剂(TCA)具有同等效力,而副作用较少。本药自1977年在欧洲面市以
Nomifensine, a “second-generation antidepressant,” began its recommended use in the United States last year and is said to be as effective as tricyclic antidepressants (TCAs) with fewer side effects. The drug since 1977 in Europe to market